苏格兰房颤患者直接口服抗凝药安全性与有效性比较
结果显示各DOAC预防卒中和系统性栓塞效果相似,但利伐沙班出血风险最高;全因死亡、心肌梗死和肺栓塞差异需进一步研究。
要点
- 各DOAC预防卒中和系统性栓塞效果相似。
- 利伐沙班出血风险最高,包括其他大出血和胃肠道出血。
- 阿哌沙班心肌梗死风险高于利伐沙班。
核心结论
- 所有DOAC在预防卒中和系统性栓塞方面效果相似,但利伐沙班出血风险最高。
- 全因死亡、心肌梗死和肺栓塞的观察差异需进一步研究。
研究设计与样本
- 回顾性队列研究,使用关联行政数据。
- 采用多变量Cox比例风险模型估计风险比。
主要发现
- 各DOAC间卒中、系统性栓塞或心血管死亡风险无差异。
- 阿哌沙班患者心肌梗死风险高于利伐沙班患者(HR 1.67,95% CI 1.02-2.71)。
- 利伐沙班患者全因死亡风险高于阿哌沙班(HR 1.22,95% CI 1.01-1.47)和达比加群(HR 1.55,95% CI 1.16-2.05)患者。
- 利伐沙班患者肺栓塞风险高于阿哌沙班患者(HR 5.27,95% CI 1.79-15.53)。
- 利伐沙班患者其他大出血风险高于阿哌沙班(HR 1.50,95% CI 1.10-2.03)和达比加群(HR 1.58,95% CI 1.01-2.48)患者;胃肠道出血和总体出血风险高于阿哌沙班患者(HR 1.48,95% CI 1.01-2.16;HR 1.52,95% CI 1.21-1.92)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The aim of this study was to compare the clinical effectiveness and safety of direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) in routine clinical practice. METHODS: This retrospective cohort study used linked administrative data. The study population (n = 14 577) included patients with a diagnosis of AF (confirmed in hospital) who initiated DOAC treatment in Scotland between August 2011 and December 2015. Multivariate Cox proportional hazard models were used to estimate hazard ratios of thromboembolic events, mortality and bleeding events. RESULTS: No differences between the DOACs were observed with regard to the risk of stroke, systemic embolism or cardiovascular death. In contrast, the risk of myocardial infarction was higher among patients prescribed apixaban in comparison to those on rivaroxaban (HR 1.67, 95% CI 1.02-2.71), and all-cause mortality was higher among rivaroxaban patients in contrast to both apixaban (1.22 [1.01-1.47]) and dabigatran (1.55 [1.16-2.05]) patients; rivaroxaban patients also had a higher risk of pulmonary embolism than apixaban patients (5.27 [1.79-15.53]). The risk of other major bleeds was higher among rivaroxaban patients compared to apixaban (1.50 [1.10-2.03]) and dabigatran (1.58 [1.01-2.48]) patients; the risks of gastrointestinal bleeds and overall bleeding were higher among rivaroxaban patients than among apixaban patients (1.48 [1.01-2.16] and 1.52 [1.21-1.92], respectively). CONCLUSIONS: All DOACs were similarly effective in preventing strokes and systemic embolisms, while patients being treated with rivaroxaban exhibited the highest bleeding risks. Observed differences in the risks of all-cause mortality, myocardial infarction and pulmonary embolism warrant further research.
引用
- Mueller T, Alvarez-Madrazo S, Robertson C, et al. Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland. Br J Clin Pharmacol. 2018. PMID: 30423191. doi:10.1111/bcp.13814
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。